Investigation of the role of rs4238001 genetic polymorphism of SR-B1 gene on serum level of lipids in Iraqi patients with myocardial infarction treated with rosuvastatin

Abstract

Abstract The scavenger receptor type B (SR-BI) is a receptor that binds both native and altered lipoproteins. It was revealed to facilitate the utilization of high-density lipoprotein HDL and significantly affect the reverse transport of cholesterol. The present work aims to explore the risk of rs4238001, a nonsynonymous genetic variant in patients of ischemic heart disease (IHD), diagnosis with myocardial infarction, and how this variant could perhaps impact the response of rosuvastatin drug. The genotyping of the rs4238001 genetic polymorphism of the SR-B1 gene was performed in 300 participants, including 150 MI patients treated with 20mg/day/4 weeks of rosuvastatin and 150 healthy using Taq man probes (FAM probe for common C allele and VIC probe for mutant T allele) by Real time-PCR technique. The concentrations of the lipid profile were evaluated. The significance of the anthropometric data was revealed in the ejection fraction and smoking status (p < 0.05) between groups. The lipid profile shows either significant differences between control and MI patient (pre-treatment) or between pre-and post-treatment of MI patients (p < 0.05), but not HDL-c (p > 0.05). The minor allele frequency MAF% of the T allele and TT genotype were more frequent in MI patients than in controls (P = 0.173; OR = 3.62; 95%CI = 0.74–17.64). CC genotype was found to be associated with response to rosuvastatin therapy with a change of % (29.08 ± 53.2; p = 0.021). In the Iraqi population, the rs4238001 polymorphism of the SR-B1 gene is associated with variations in serum lipids, and the CC genotype of the SNP is related to higher HDL-C in the lipid-lowering rosuvastatin response.